I was in the media bullpen with the team when the future arrived.

The launch of Roferon-A, alpha interferon marked a watershed moment in medicine: the first biotherapeutic to treat cancer, targeting the rare disease hairy-cell leukemia. I remember the packed press conference at The Pierre Hotel in New York City. Thought leaders like Dr. Jerome Groopman inspired awe. Headlines followed. The world paid attention.

That was decades ago. Since then, the biotech sector has evolved from fragile start-up spirit into a multibillion-dollar force. In the eyes of many, what was once miraculous has become mundane. And yet, the science has only grown more awe-inspiring. So why don’t we talk about it that way anymore?

Have we become numb to the very progress that extends and saves lives?

Biotechnology is arguably one of humanity’s most transformative achievements. From precision cancer immunotherapies to gene editing tools like CRISPR, we’ve leapt across medical milestones that were once the stuff of science fiction. CAR-T cell therapy rewrites the body’s immune system; mRNA platforms taught us how to respond to pandemics in real time; and personalized medicine now tailors treatments to the uniqueness of our DNA.

Despite these triumphs, we now face a paradox: the more frequently we succeed, the less exceptional it seems. Biotech, in its reliability, risks becoming background noise.

The danger here isn’t just perception—political, economic, and moral. When we stop being amazed, we stop advocating. And advocacy is essential, because science doesn’t fund itself.

The Birth of a Movement: BIO’s Role in Advancing Innovation

In the early days of this field, the promise of biotech required more than scientific breakthroughs—it demanded an organized, united voice to advocate for science, policy, funding, and public trust. That’s when the Biotechnology (Industry) Innovation Organization (BIO) emerged, uniting a fledgling industry around a shared mission: to promote innovation and ensure that the fruits of biotech reach the people who need them most.

What began as a coalition of pioneers has evolved into one of the most influential global voices for biotechnology. BIO has helped shape legislation, fostered partnerships, supported startups, and advanced equity in access and clinical trials. It has been a tireless advocate for the idea that science serves people—and that innovation without access is innovation incomplete.

As we reflect on biotech’s journey—from niche science to essential public health engine—BIO’s efforts to engage policymakers, educate the public, and convene global stakeholders at events like the annual BIO International Convention, BIO2025 have played a defining role. It’s a reminder that scientific progress is never just about the petri dish. It’s about ecosystems—coalitions of scientists, communicators, investors, and institutions aligned toward a common good.

The Threat of Institutional Apathy

Innovation doesn’t flourish in a vacuum. It requires funding, partnerships, regulatory foresight, and yes, public interest. Today, with DOGE pinching national budgets and partisanship clouding consensus, Federal funding for research is under threat. The National Institutes of Health (NIH), the world’s largest public funder of biomedical research, faces increasingly skeptical eyes and plummeting appropriations.

In parallel, biotech investors—once exuberant—have become cautious. Valuations are down. IPO windows are narrow. Even promising start-ups are forced to downsize or shutter. This isn’t just an economic cycle. It’s a societal test.

If we stop investing in innovation, diseases that could have been conquered will remain entrenched. Rare conditions will stay rare because they’re unprofitable. And the promise of personalized, preventive care will fade back into abstraction. Let’s take stock.

We’ve made incredible strides in HIV, hepatitis C, certain leukemias, and now we see glimpses of progress in previously unyielding diseases like ALS and pancreatic cancer. In some cases, such as HIV, biologics have helped turn some diseases into manageable conditions. Patients who once faced death sentences now live long, productive lives.

But so much work remains. Alzheimer’s disease continues to challenge us. Autoimmune conditions like lupus and Crohn’s demand better solutions. Pediatric rare diseases—often overlooked—leave families desperate for options. And mental health, despite its growing visibility, remains underfunded and underexplored from a biotherapeutic standpoint.

We can’t stop now. The urgency is not over.

Science Needs Storytellers

One of the most potent forces in advancing biotherapeutics isn’t just the lab bench—it’s the lens through which the public sees that bench. This is where communicators come in.

Media, public relations professionals, and advocacy leaders are not passive observers. We are active players in this ecosystem. When we frame scientific progress as human progress, we drive interest, funding, and talent into the field. When we tell stories that connect molecules to people, we give science a face—and a heartbeat.

In the early days of Roferon-A, calls from a young PR pro would turn out a full-room press conference, launching a wave of national interest. Today, the media landscape is fragmented. Clicks compete with credibility, and sensationalism wins over substance.

That only means our responsibility has grown. We must elevate the authentic voices of scientists, patients and advocates. We must cover biotech stories not just as business news, but as human stories, because they convey the struggle and potential.

Bench to Bedside is a Human Endeavor

Behind every molecular breakthrough is a researcher who missed birthdays to run experiments, a trial participant who volunteered without knowing the outcome, and a caregiver hoping that science can offer one more chance. We cannot allow their efforts to be invisible.

Let us remember that biotherapeutics are not just lab products—they are the embodiment of human hope and courage. Each FDA approval to market is a victory for a company and a patient.

And yet, even as we acknowledge this, we must grapple with another complexity: equity.

Not all communities have equal access to these innovations. Biologics are expensive. Insurance structures are slow to adapt, sometimes even resisting. Global disparities persist. If we believe in the power of biotech, we must also commit to making it accessible, advocating for affordability, inclusive clinical trials and compassionate pricing strategies.

Reclaiming the Wonder

So, where do we go from here?

We start by reawakening awe. As communicators, we must use our platforms to remind the world that biotech is not just another industry—it is a movement, a mission.

We must protect the budgets that sustain research, defend the credibility of science against misinformation, and inspire young minds to enter STEM fields not just for jobs but for the opportunity to change lives.

It starts with how we talk. Let’s use language that evokes possibility. Let’s tell stories that illuminate the patient journey. Let’s spotlight scientists with the same reverence we show to athletes or entertainers.

Biotech Without Borders

The original promise of biotechnology was to break boundaries between disciplines, possibilities, and life and death. That promise is still alive, but it needs guardians.

Now more than ever, biotech needs communicators, policymakers, and citizens who care.

I remember the days when biotech press conferences made front pages. Maybe we’ll never go back to that exact moment. But we can choose to go forward—together—into a future where science is again seen not just as data, but as destiny.

Let’s reclaim the wonder. Let’s continue to give scientists a voice, patients hope, start-up enterprises resources, and policymakers direction.

Because what’s at stake is not just the next miracle drug.  What’s at stake is our collective belief that we can still do miraculous things.